Hosted on MSN
Harrow wins FDA clearance to launch phase 3 trial aimed at expanding TRIESENCE label in cataract surgery
Harrow (NASDAQ:HROW) said Tuesday that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application, paving the way for a Phase 3 clinical trial of TRIESENCE® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results